Vita Life Sciences Expects H1 Sales to Increase From a Year Earlier

MT Newswires Live
06/12

Vita Life Sciences (ASX:VLS) expects a pre-tax profit of AU$6.8 million to AU$7.3 million and sales of AU$46.3 million to AU$47.3 million for the half year ending June 30, according to a Friday filing with the Australian bourse.

For the first half of 2025, the company booked a pre-tax profit of AU$6.8 million on sales of AU$45.5 million, per the filing.

Vita Life Sciences said it expects "solid revenue growth" in the markets of Australia, Malaysia, and Singapore, partially offset by lower exports to China amid a shifting regulatory landscape and channel dynamics.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10